These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16776860)

  • 1. Tibolone is not used as a first-line therapy: implications for the Million Women Study analysis.
    Seeley T
    J Br Menopause Soc; 2006 Jun; 12(2):81. PubMed ID: 16776860
    [No Abstract]   [Full Text] [Related]  

  • 2. Interaction between hormone replacement therapy preparations and oral anticoagulant therapy.
    McLintock LA; Dykes A; Tait RC; Walker ID
    BJOG; 2003 Aug; 110(8):777-9. PubMed ID: 12892692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of menopause and tibolone on different cardiovascular biomarkers in healthy women.
    Vassalle C; Cicinelli E; Lello S; Mercuri A; Battaglia D; Maffei S
    Gynecol Endocrinol; 2011 Mar; 27(3):163-9. PubMed ID: 20500110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reasons for abandonment of hormone replacement therapy with tibolone in menopausal women].
    Zayas-Jaime FJ; Ornelas-Aguirre JM; Pérez-Nápoles DE
    Ginecol Obstet Mex; 2013 Oct; 81(10):593-601. PubMed ID: 24483042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of different hormonal therapies on thyroid function in surgical menopause: short-term results.
    Erel CT; Gezer A; Sentürk LM; Somunkiran A; Kaleli S; Seyisoglu H
    J Reprod Med; 2007 Dec; 52(12):1079-84. PubMed ID: 18210897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
    Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
    Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of tibolone on ocular functions in postmenopausal women.
    Verit FF; Oguz H; Ozkul Y; Bozkurt O
    Arch Gynecol Obstet; 2007 Apr; 275(4):255-61. PubMed ID: 17047975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hormone replacement therapy on insulin resistance and platelet function tests.
    Saraç F; Saydam G; Sahin F; Oztekin K; Saygili F; Tüzün M; Yilmaz C
    Med Princ Pract; 2009; 18(1):43-7. PubMed ID: 19060490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women.
    Ribom EL; Svensson P; van Os S; Larsson M; Naessen T
    Menopause; 2011 Feb; 18(2):194-7. PubMed ID: 20689464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term hormone treatment and of tibolone on monoamines and monoamine metabolites in the brains of ovariectomised, Cynomologous monkeys.
    Gibbs RB; Edwards D; Lazar N; Nelson D; Talameh J
    J Neuroendocrinol; 2006 Sep; 18(9):643-54. PubMed ID: 16879163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy--differing guidelines.
    Cheifitz RL
    S Afr Med J; 2005 Apr; 95(4):232, 234, 236 passim. PubMed ID: 15889844
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors.
    Skouby SO; Sidelmann JJ; Nilas L; Gram J; Jespersen J
    Climacteric; 2008; 11(6):489-97. PubMed ID: 18991076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability.
    Skouby SO; Sidelmann JJ; Nilas L; Jespersen J
    Hum Reprod; 2007 Apr; 22(4):1186-91. PubMed ID: 17204528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmenopausal HRT and tibolone in relation to muscle strength and body composition.
    Jacobsen DE; Samson MM; Kezic S; Verhaar HJ
    Maturitas; 2007 Sep; 58(1):7-18. PubMed ID: 17576043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive effects of 10 years of hormone-replacement therapy with tibolone.
    Fluck E; File SE; Rymer J
    J Clin Psychopharmacol; 2002 Feb; 22(1):62-7. PubMed ID: 11799344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial cancer--surprising reports.
    Speroff L
    Maturitas; 2005 Aug; 51(4):329-33. PubMed ID: 16039404
    [No Abstract]   [Full Text] [Related]  

  • 18. Tibolone low dose (1.25 mg/d) therapy and postural balance in elderly women.
    Naessen T; Lindmark B; Larsen HC; van Os S; Larsson M
    Maturitas; 2009 Jan; 62(1):72-5. PubMed ID: 19097714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of tibolone on the reduction of menopausal problems--a Bayesian semi-parametric interpretation.
    Das K; Naskar M
    Stat Med; 2007 Mar; 26(6):1301-17. PubMed ID: 16900555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.